Three trials of indoprofen.
Three trials have been used to document various properties of indoprofen. As a simple analgesic, indoprofen (200 mg) was superior to placebo and at least as effective as aspirin (700 mg). As an anti-inflammatory, indoprofen (200 mg four times daily) was superior to both ibuprofen (300 mg four times daily) and placebo. With regular administration, the effect of indoprofen reached a plateau within 24 hours of the start of treatment. Long term administration confirmed the safety of indoprofen and the overall incidence of side effects was similar to that associated with ibuprofen therapy. Equal numbers of patients were withdrawn from the indoprofen and ibuprofen groups but the reasons for withdrawal were different. Patients were withdrawn from the ibuprofen group because of lack of effect and from the indoprofen group because of gastric side effects.
D000893:Anti-Inflammatory Agents / Q000494:pharmacology*; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000494:pharmacology*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy; D001241:Aspirin / Q000494:pharmacology; D002986:Clinical Trials as Topic; D004064:Digestive System / Q000187:drug effects; D006801:Humans; D007052:Ibuprofen / Q000494:pharmacology; D007216:Indoprofen / Q000494:pharmacology*; D010666:Phenylpropionates / Q000494:pharmacology*; D010919:Placebos; D011897:Random Allocation
D000893:Anti-Inflammatory Agents; D000894:Anti-Inflammatory Agents, Non-Steroidal; D010666:Phenylpropionates; D010919:Placebos; D007216:Indoprofen; D001241:Aspirin; D007052:Ibuprofen